[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bronchitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bronchitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,79,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100641959","phase-3-clinical-trial-of-the-efficacy-and-safety-of-raphamin-in-the-treatment-of-acute-bronchitis-in-adult-patients-100641959",false,"NCT07650227","Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients","Multicenter, Double Blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients","Inclusion Criteria:\n\n1. Male and female patients aged 18 to 64 years, inclusive.\n2. Confirmed diagnosis of acute bronchitis (AB) based on the presence of productive cough and one or more symptoms (wheezing in the lungs, chest \"discomfort\", shortness of breath, fever).\n3. The BSS score of at least 5 and no more than 15 points.\n4. Duration of AB symptoms does no more than 72 hours.\n5. Seasonal incidence of acute respiratory viral infections.\n6. Availability of a patient information sheet and an informed consent form for participation in the clinical trial signed by the patient.\n7. Patients who have agreed to use a reliable method of contraception during the study (for men and women of reproductive potential).\n\nExclusion Criteria:\n\n1. History of chronic obstructive pulmonary disease, chronic bronchitis, asthma, bronchiectasis, or pulmonary emphysema.\n2. Suspected pneumonia or bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.) requiring antibiotics, starting on the first day of illness.\n3. Suspected infiltrative pulmonary tuberculosis, pulmonary embolism, pulmonary infarction, drug-induced (toxic) pneumopathy, foreign body aspiration, sarcoidosis, pulmonary alveolar proteinosis, lipoid pneumonia, or atelectasis.\n4. History of immunopathological diseases: systemic vasculitis, lupus pneumonitis, allergic bronchopulmonary aspergillosis, obliterating bronchiolitis, idiopathic pulmonary fibrosis, eosinophilic pneumonia, bronchocentric granulomatosis.\n5. Chronic heart failure with functional classes III and IV (according to the classification of the New York Heart Association, 1964).\n6. Metabolic disorders (obesity grades 2-3).\n7. History of chronic kidney disease (classes C3-5 A3); liver failure (class C according to Child-Pugh); neurological conditions (neuromuscular, neurocognitive disorders, epilepsy); hemoglobinopathy.\n8. Primary and\u002For secondary immunodeficiency (HIV infection, administration of immunosuppressive drugs, etc.).\n9. Surgery of any localization within the last 3 months.\n10. Clinical symptoms of severe influenza\u002FARI requiring hospitalization .\n11. Acute respiratory failure.\n12. History\u002Fsuspected oncological disease of any location (except for benign neoplasms).\n13. Exacerbation or decompensation of chronic diseases that affect the patient's ability to participate in the clinical trial, including diabetes mellitus.\n14. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.\n15. Pregnancy, breastfeeding, and childbirth less than 3 months prior to study inclusion.\n16. Hypersensitivity to any component of the medications used in the treatment.\n17. Patients who have taken medications listed in the \"Prohibited Concomitant Medication\" section in the previous 1 month prior to study inclusion or who require medications prohibited for use in this study.\n18. Patients who, in the investigator's opinion, will not comply with study monitoring requirements or with the study drugs administration schedule.\n19. History of mental illness, alcoholism, or drug abuse that, in the investigator's opinion, will interfere with successful compliance with study procedures.\n20. Participation in other clinical trials within 3 months prior to study inclusion.\n21. The patient is a member of the center's research staff directly involved in the study and is an immediate family member of the investigator. Immediate family members are defined as spouses, parents, children, or siblings, regardless of whether they are biological or adopted.\n22. The patient is employed by NPF MATERIA MEDICA HOLDING LLC, i.e., is an employee of the company, a temporary contract worker, or a designated official responsible for the study, or is an immediate family member of one of these individuals..","ALL","18 Years","64 Years",{"count":20,"type":21},308,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to learn if Raphamin works to treat acute bronchitis in adults. It will also learn about the efficacy and the safety of Raphamin. The main questions it aims to answer are:\n\nWill treatment with Rafamine contribute to a faster resolution of acute bronchitis symptoms, reduce the severity of the disease, and prevent the development of complications requiring antibacterial therapy compared to placebo therapy? Investigators will compare Raphamin to a placebo (a look-alike substance that contains no drug) to see if Raphamin works to treat acute bronchitis.\n\nParticipants will:\n\nTake Raphamin or a placebo for 5 days. On the first day of treatment 8 tablets of Raphamin or a placebo should be taken using the following regimen: 1 tablet every 30 minutes for the first 2 hours (5 tablets in total for 2 hours), then 1 more tablet 3 times at equal intervals during the same day. On day 2 and onwards, 1 tablet should be taken 3 times a day.\n\nFace-to-face visits are planned in the trial: Visit 1 (Day 1), Visit 2 (Day 4±1), Visit 3 (Day 7±1), and a phone Visit 4 (day 14±1). The study uses an electronic patient diary (EPD) in which symptoms of acute bronchitis (cough, sputum, chest pain during coughing) are assessed daily.",[27,28],"Bronchitis","Acute Bronchitis",[27,30,31],"Acute","Adults","RECRUITING","2026-06-24",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":36},"2025-12-09",{"date":40,"type":21},"2028-12-31",{"name":42,"class":43},"Materia Medica Holding","INDUSTRY",33,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100554125","how-omt-benefits-newly-diagnosed-patients-with-respiratory-illness-when-given-alongside-other-standard-care-100554125","NCT06495021","How OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care.","OMT and Respiratory Illness","Inclusion Criteria:\n\n* Patients being seen for respiratory illness symptoms at Geisinger 65-Forward Buckhorn, PA clinic for care.\n* Patients age of 65-100\n* New diagnosis of upper respiratory illness, sinusitis, bronchitis, or pneumonia during outpatient visit.\n\nExclusion Criteria:\n\n* Patients that have a healing fracture, including the spine, pelvis, shoulder, ribs, vertebrae, or extremities.\n* Patients actively receiving any type of cancer treatment\n* Patients with active or previously diagnosed liver disease.","65 Years","100 Years",{"count":55,"type":21},68,[57],"NA","This study is to see Osteopathic Manipulative Therapy, or OMT, can aid in treating patients being seen for respiratory illness and associated symptoms. The hypothesis is that the addition of OMT therapy, alongside other standard care (such as a medication), can help lessen patient symptoms sooner than just other treatment alone, and the duration of the condition will shorten as well.",[60,61,27,62,63],"Pneumonia","Sinusitis","Respiratory Disease","Respiratory Tract Infections",[65,66,67],"Osteopathic Manual Therapy","Respiratory Illness","OMT","2025-07-07",{"date":70,"type":36},"2025-07-08",{"date":72,"type":36},"2024-12-31",{"date":74,"type":21},"2026-06",{"name":76,"class":77},"Geisinger Clinic","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":78},"100586891","development-of-the-drug-and-alcohol-respiratory-health-test-100586891","NCT06921278","Development of the Drug and Alcohol Respiratory Health Test","Psychometric Development of the Alcohol and Drug Respiratory Health Questionnaire and Evaluation of a Lung Health Clinic","DARHT","Inclusion Criteria:\n\n1. \\>18 (no upper age limit)\n2. Inhalation (smoking) of tobacco, or cannabis, or cocaine, or opioids, or use of alcohol in the past 28 days\n3. Possession of a personal mobile phone to arrange follow-up appointments\n\nExclusion Criteria:\n\n1. Reported physical health condition that would mean spirometry contra-indicated - including heart attack, unstable angina, pulmonary embolism,\n2. Reported surgery in the past 3 months for an eye, chest, or abdominal condition that would mean spirometry contra-indicated\n3. Likely inability to complete study due to criminal justice involvement with legal proceedings risking incarceration",{"count":88,"type":21},260,"OBSERVATIONAL","The goal of this study is to develop a brief Drug and Alcohol Respiratory Health Test (DARHT) and offer it for routine use in clinical assessment and medical reviews",[62,92,93,94,95,96,27,60,97],"Substance-Related Disorders","COPD","Asthma","Lung Cancer","Tuberculosis","Obstructive Sleep Apnea","NOT_YET_RECRUITING","2025-04-03",{"date":101,"type":36},"2025-04-10",{"date":103,"type":21},"2025-04-15",{"date":105,"type":21},"2025-11-11",{"name":107,"class":77},"King's College London",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":116,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":118,"conditions":119,"keywords":133,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":78},"100556693","identification-of-multiple-pulmonary-diseases-using-volatile-organic-compounds-biomarkers-in-human-exhaled-breath-100556693","NCT06528418","Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","Exploration and Study on the Identification of Various Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","Inclusion Criteria:\n\n* Males or females, age must be 18 years old or above.\n* Patients must meet the CT imaging diagnostic criteria for different lung diseases, and patients must be able to provide electronic versions of CT image data.\n* Patients must have a clear clinical diagnosis.\n* All participants must sign a written informed consent form.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Individuals with a history of cancer other than lung disease.\n* Individuals who have undergone organ transplants or non-autologous (allogeneic) bone marrow or stem cell transplants.\n* Individuals with other severe organic diseases or mental illnesses.\n* Individuals with metabolic diseases such as diabetes, hyperlipidemia, etc.\n* Any other condition that researchers deem unsuitable for participation in this clinical trial.",true,{"count":117,"type":21},10000,"The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model aims to accurately diagnose mutiple pulmonary diseases. The primary objectives it strives to accomplish are:\n\n1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose several common pulmonary diseases.\n2. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose more pulmonary diseases.",[95,120,93,27,121,122,123,124,125,126,127,128,129,130,131,132],"Lung Infection","Pulmonary Fibrosis","Pulmonary Embolism","Pulmonary Arterial Hypertension","Pulmonary Tuberculosis","Pulmonary Abscess","Emphysema","Lung Injury","Cystic Fibrosis of the Lung","Bronchial Asthma","Bronchiectasis","Interstitial Lung Disease","Preserved Ratio Impaired Spirometry",[134,135,136,137,138],"Pulmonary Disease","Volatile Organic Compounds","Human Exhaled Breath","micro Gas Chromatography-photoionisation","detector (μGC-PID) system","2025-03-23",{"date":141,"type":36},"2025-03-26",{"date":143,"type":36},"2024-06-30",{"date":145,"type":21},"2027-06-30",{"name":147,"class":43},"ChromX Health"]